Tango Therapeutics (TNGX) Net Cash Flow Growth (1y) (2021 - 2026)
Tango Therapeutics (TNGX) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Tango Therapeutics | 3.86 Bn | 3.70 Bn | - | 506.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 506.57% |
| Dec 31, 2025 | 229.27% |
| Sep 30, 2025 | 1,105.18% |
| Jun 30, 2025 | -99.65% |
| Mar 31, 2025 | -82.59% |
| Dec 31, 2024 | 108.63% |
| Sep 30, 2024 | 121.04% |
| Jun 30, 2024 | -209.06% |
| Mar 31, 2024 | -85.14% |
| Dec 31, 2023 | 119.46% |
| Sep 30, 2023 | -76.09% |
| Jun 30, 2023 | 88.32% |
| Mar 31, 2023 | 92.02% |
| Dec 31, 2022 | 35.17% |
| Sep 30, 2022 | -102.77% |
| Jun 30, 2022 | 131.39% |
| Mar 31, 2022 | -209.93% |
| Dec 31, 2021 | -4,835.54% |
| Sep 30, 2021 | 9,825.87% |
| Jun 30, 2021 | -59,672.68% |